Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

by B2i | Nov 20, 2023 | Press Releases

JUPITER, Fla., Nov. 20, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

by B2i | Nov 8, 2023 | Press Releases

Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme products DYAI-100 Phase 1 clinical trial top-line results expected in December 2023 New research collaboration with...

Dyadic to Present at Industry Events in November

by B2i | Oct 30, 2023 | Press Releases

JUPITER, Fla., Oct. 30, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

by B2i | Oct 25, 2023 | Press Releases

JUPITER, Fla., Oct. 25, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic Appoints Doug Pace to Its Executive Leadership Team

by B2i | Oct 9, 2023 | Press Releases

JUPITER, Fla., Oct. 09, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases

by B2i | Oct 5, 2023 | Press Releases

JUPITER, Fla., Oct. 05, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...